Soluble GP130 muteins with improved binding activity

US8501696B2 · kind B2 · utility

Assignee

• CONARIS Research Institute AG · DE

Inventors

• Joachim Grötzinger · Altwittenbek, DE
• Jürgen Scheller · Neuss, DE
• Stephanie Tenhumberg · Schwetzingen, DE
• Stefan Rose-John · Kiel, DE
• Georg H. Wätzig · Kiel, DE

Key dates

• Filing date: Oct 15, 2008
• Grant date: Aug 6, 2013
• Expiry date: Apr 17, 2029

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N33/6893
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

Described are soluble gp130 polypeptide monomers and dimers, wherein, in a preferred embodiment, at least one of the three amino acid residues Thr102 Gln113 or Asn114 of the N-terminal Ig-like domain of gp130 is mutated to Tyr102, Phe113 or Leu114, respectively. These mutations, alone or in combination, specifically enhance binding of gp130 to its ligand complex of interleukin-6 and soluble interleukin-6 receptor, thus increasing the biological activity of the gp130 muteins. In a particularly preferred embodiment, all three mutations are combined in the triple mutein Thr102Tyr/Gln113Phe/Asn114Leu (T102Y/Q113F/N114L). Moreover, a pharmaceutical composition containing said monomers or dimers and various medical uses are described.